Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761444 | 0.98 | ACMSD (0.45) | ACMSDTDP1PTGS2PSMB5HDAC1 | |
| SCHEMBL29111655 | 0.98 | ACMSD (0.45) | ACMSDTDP1PTGS2PSMB5HDAC1 | |
| SCHEMBL10793646 | 0.98 | ACMSD (0.45) | ACMSDTDP1PTGS2PSMB5HDAC1 | |
| SCHEMBL6980151 | 0.93 | ACMSD (0.44) | ACMSDTDP1PTGS2PSMB5HDAC1 | |
| SCHEMBL10793933 | 0.83 | ACMSD (0.53) | ACMSDTDP1PTGS2PSMB5HDAC1 | |
| SCHEMBL28019816 | 0.80 | — | — | |
| SCHEMBL676952 | 0.77 | ACMSD (0.36) | ACMSDTDP1PTGS2PSMB5HDAC1 | |
| SCHEMBL8380044 | 0.76 | ACMSD (0.49) | ACMSDTDP1PTGS2MEN1KMT2A | |
| SCHEMBL191429 | 0.76 | ACMSD (0.49) | ACMSDTDP1PTGS2MEN1KMT2A | |
| SCHEMBL8360447 | 0.74 | ACMSD (0.47) | ACMSDTDP1PTGS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | claimed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | claimed |
| WO-2021249969-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2021-12-16 | — | — | WO | claimed |
| EP-3898588-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | claimed |
| CN-107528006-B | Organic light emitting device | 三星显示有限公司 | 2021-03-19 | — | — | CN | claimed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | claimed |
| EP-2786985-B1 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | claimed |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2016-01-14 | — | — | US | claimed |
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| CN-101610995-A | Novel glucagon receptor antagonists | METABASIS THERAPEUTICS INC (US) | 2009-12-23 | — | — | CN | claimed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-20040220413-A1 | Method of producing optically active aziridine compounds and amine compounds | KYUSHU UNIVERSITY (JP) | 2004-11-04 | — | — | US | claimed |
| EP-1449831-A1 | Method of producing optically active aziridine compounds and amine compounds | Kyushu University (JP) | 2004-08-25 | — | — | EP | claimed |
| US-4677184-A | Polycarbonate containing cycloalkenylphenyl terminal groups | GENERAL ELECTRIC COMPANY (US) | 1987-06-30 | — | — | US | claimed |
| CN-111826169-B | Liquid crystal composition, use thereof, and liquid crystal display element | 捷恩智株式会社 | 2024-03-19 | — | — | CN | disclosed |
| CN-117247323-A | Amine compound and organic light emitting device including the same | 三星显示有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-4032461-A | PHOSPHORUS AND SULFUR CONTAINING AMIDES AND THIOAMIDES AS LUBRICATING OIL ADDITIVES AND LUBRICATING OIL COMPOSITIONS CONTAINING SAME | THE LUBRIZOL CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4031023-A | Lubricating compositions and methods utilizing hydroxy thioethers | THE LUBRIZOL CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
| US-4011332-A | RODENTICIDE | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ACMSD 3297/4885TDP1 4549/4885PTGS2 2305/4885 |
| US-20040220413-A1 | Method of producing optically active aziridine compounds and amine compounds | AOC2, AZI2, SRM | ACMSD 139/4885TDP1 3968/4885PTGS2 1468/4885 |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | ACMSD 4722/4885TDP1 805/4885PTGS2 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.